Benjamin L. Palleiko
Overview
Benjamin L. Palleiko received an average of $2M in total compensation, including $403K in salary, at Carbylan Therapeutics from 2017 to 2023.
2023Carbylan TherapeuticsPresident, Chief Business Officer and Chief Financial Officer
2022Carbylan TherapeuticsPresident, Chief Business Officer and Chief Financial Officer
2021Carbylan TherapeuticsPresident, Chief Business Officer and Chief Financial Officer
2020Carbylan TherapeuticsChief Business Officer and Chief Financial Officer
2019Carbylan TherapeuticsChief Business Officer and Chief Financial Officer
2018Carbylan TherapeuticsChief Business Officer and Chief Financial Officer
2017Carbylan TherapeuticsChief Business Officer and Chief Financial Officer
Source: SEC filings on August 14, 2023, August 25, 2020, and August 23, 2019.
Related executives
We found six more executives who work or worked at Carbylan Therapeutics.
T Crockett
Carbylan Therapeutics
Chief Executive Officer
Christopher Yea
Carbylan Therapeutics
Chief Development Officer
Edward Feener
Carbylan Therapeutics
Chief Scientific Officer
David Renzi
Carbylan Therapeutics
Chief Operating Officer
Premchandran Ramiya
Carbylan Therapeutics
Vice President, Pharmaceutical Development & Supply Chain
Marcee Maroney
Carbylan Therapeutics